A Highly Potent and Cellularly Active β-Peptidic Inhibitor of the p53/hDM2 Interaction

被引：15
作者：
Hintersteiner, Martin [1 ,2 ]
Kimmerlin, Thierry [2 ]
Garavel, Geraldine [2 ]
Schindler, Thorsten [2 ]
Bauer, Roman [2 ]
Meisner, Nicole-Claudia [2 ]
Seifert, Jan-Marcus [2 ]
Uhl, Volker [2 ]
Auer, Manfred [1 ,2 ]
机构：
[1] Univ Edinburgh, Ctr Translat & Chem Biol, Edinburgh EH9 3JR, Midlothian, Scotland
[2] Novartis Inst BioMed Res, Innovat Screening Technol Unit, A-1235 Vienna, Austria
来源：
CHEMBIOCHEM | 2009年 / 10卷 / 06期
关键词：
antitumor agents; beta-peptides; hDM2; inhibitors; p53; protein-protein interactions; HELICAL SECONDARY STRUCTURE; PROTEINOGENIC SIDE-CHAINS; DRUG DISCOVERY; GAMMA-PEPTIDES; DOMAIN; P53; ACIDS;
D O I：
10.1002/cbic.200800803
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
[No abstract available]
引用
收藏
页码：994 / 998
页数：5
相关论文
共 50 条
  • [21] Effect of linker on the binding free energy of stapled p53/HDM2 complex
    Im, Haeri
    Ham, Sihyun
    PLOS ONE, 2020, 15 (04):
  • [22] Targeting p53, hdm2, and CD19: vaccination and immunologic strategies
    R-H Voss
    C Lotz
    A Cellary
    M Theobald
    Bone Marrow Transplantation, 2000, 25 : S43 - S45
  • [23] The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure
    Zhao, JH
    Wang, MJ
    Chen, J
    Luo, AP
    Wang, XQ
    Wu, M
    Yin, DL
    Liu, ZH
    CANCER LETTERS, 2002, 183 (01) : 69 - 77
  • [24] An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs
    Laín, S
    Midgley, C
    Sparks, A
    Lane, EB
    Lane, DP
    EXPERIMENTAL CELL RESEARCH, 1999, 248 (02) : 457 - 472
  • [25] 5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2
    Dickens, Michael P.
    Roxburgh, Patricia
    Hock, Andreas
    Mezna, Mokdad
    Kellam, Barrie
    Vousden, Karen H.
    Fischer, Peter M.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (22) : 6868 - 6877
  • [26] Implementation of a 220,000-Compound HCS Campaign to Identify Disruptors of the Interaction between p53 and hDM2 and Characterization of the Confirmed Hits
    Dudgeon, Drew D.
    Shinde, Sunita
    Hua, Yun
    Shun, Tong Ying
    Lazo, John S.
    Strock, Christopher J.
    Giuliano, Kenneth A.
    Taylor, D. Lansing
    Johnston, Patricia A.
    Johnston, Paul A.
    JOURNAL OF BIOMOLECULAR SCREENING, 2010, 15 (07) : 766 - 782
  • [27] Activated Akt expression in breast cancer: Correlation with p53, Hdm2 and patient outcome
    Vestey, SB
    Sen, C
    Calder, CJ
    Perks, CM
    Pignatelli, M
    Winters, ZE
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (07) : 1017 - 1025
  • [28] Nucleophosmin, HDM2 and p53 - Players in UV damage incited nucleolar stress response
    Kurki, S
    Peltonen, K
    Laiho, M
    CELL CYCLE, 2004, 3 (08) : 976 - 979
  • [29] Hdm2 disrupts HdmX-mediated nuclear export of p53 by sequestering it in nucleus
    Ni, Yue
    Chen, Hongce
    Cheng, Xuecheng
    Sun, Beini
    Wu, Zhirui
    Zhan, Qiuqiang
    Zhuang, Zhengfei
    EXPERIMENTAL CELL RESEARCH, 2024, 441 (02)
  • [30] Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib
    Ooi, Melissa G.
    Hayden, Patrick J.
    Kotoula, Vassiliki
    McMillin, Douglas W.
    Charalambous, Elpida
    Daskalaki, Emily
    Raje, Noopur S.
    Munshi, Nikhil C.
    Chauhan, Dharminder
    Hideshima, Teru
    Buon, Leutz
    Clynes, Martin
    O'Gorman, Peter
    Richardson, Paul G.
    Mitsiades, Constantine S.
    Anderson, Kenneth C.
    Mitsiades, Nicholas
    CLINICAL CANCER RESEARCH, 2009, 15 (23) : 7153 - 7160
12345